Zydus Lifesciences share price: The company’s share price surged 6.3 per cent to hit life-high of Rs 1,083 apiece after it posted strong Q4FY26 results. The earnings drew bullish brokerage calls on Zydus Lifesciences share price, with analysts highlighting potential upside driven by improving margins and a favourable business mix. The stock however at market open breached the share price target given by both Nuvama and Motilal Oswal.
The company posted a consolidated net profit of Rs 1,272.5 crore, up 8.7 per cent year-on-year, while revenue climbed 16 per cent to Rs 7,587 crore, supported by robust growth in the US and MedTech segments. Despite one-off expenses weighing on reported earnings, healthy operational momentum and margin expansion have led to upgrades and higher earnings estimates, even as brokerages remain watchful of near-term moderation in the US business.
Nuvama On Zydus Lifesciences
Motilal Oswal On Zydus Lifesciences
Zydus Lifesciences Q4FY26
Zydus Lifesciences reported a rise in reported net profit for Q4FY26, despite a sharp increase in one-off expenses, as strong operational performance and margin expansion cushioned the impact of exceptional items.
The company posted a reported net profit of Rs 1272.5 crore, up 8.7 percent year-on-year, while adjusted net profit rose 15 percent to Rs 1592.9 crore, reflecting underlying strength across key businesses. The divergence between reported and adjusted profit was driven by a Rs 397.5 crore one-time expense related to a Mirabegron litigation settlement, as well as other exceptional costs during the quarter.
Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26. Revenue from operations rose 16 percent year-on-year to Rs 7587 crore, while EBITDA grew faster at 20 percent, expanding margins by 110 basis points to 33.7 percent.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
